News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Archemix Corporation and NascaCell Expand Strategic Alliance for Aptamer-Based Drug Discovery
February 12, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass. & MUNICH, Germany--(BUSINESS WIRE)--Archemix Corp. and NascaCell Technologies AG announced today an expansion of their strategic alliance focused on the use and development of aptamers for drug discovery applications.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Europe
MORE ON THIS TOPIC
Mergers & Acquisitions
Lilly lands vaccine trifecta with 3 new biotech buys valued at up to $3.8B
May 26, 2026
·
5 min read
·
Annalee Armstrong
Business
Lilly is pharma’s top dog, placing first in innovation and invention: IDEA
May 26, 2026
·
2 min read
·
Tristan Manalac
Funding
Recordati fields $12.4B go-private offer
May 22, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Gilead inks $140M API supply deal, tightening ties to Korean manufacturer
May 22, 2026
·
1 min read
·
Nick Paul Taylor